InvestorsHub Logo

H2R

Followers 42
Posts 2161
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: Rymankoly post# 4273

Tuesday, 10/10/2017 10:19:49 AM

Tuesday, October 10, 2017 10:19:49 AM

Post# of 4817
Hi Rymankoly,

I see it as a bullish move prior to the FDA decision too :) See Robert Apple statement: Cash, no dilution, get ready to fuel the commercial launch. That sounds confident to me:

Today’s announcement represents another milestone in executing on our long-term strategic plan. We are very pleased that Ferring has purchased the ZOMAJET business in order to consolidate the ZOMACTON franchise,” said Robert F. Apple, President and Chief Executive Officer of Antares. “The sale of a non-core legacy asset which represented approximately $5.5 million annual revenue in the past three years, will allow Antares to better focus its resources on several key strategic objectives which we believe may increase shareholder value. The transaction with Ferring generates additional non-dilutive cash which Antares intends to use to invest in our pipeline in addition to supporting the potential launch of our next proprietary product, XYOSTED. The XYOSTED New Drug Application is currently under active review at the U.S. Food and Drug Administration (FDA) and we are working closely with the FDA toward a potential approval in October.


https://seekingalpha.com/pr/16963493-antares-pharma-announces-sale-zomajet-needle-free-delivery-system-ferring-pharmaceuticals